Literature DB >> 8977452

LDL stimulates chemotaxis of human monocytes through a cyclooxygenase-dependent pathway.

J Kreuzer1, S Denger, L Jahn, J Bader, K Ritter, E von Hodenberg, W Kübler.   

Abstract

Monocyte migration into the vessel wall is an early step in atherogenesis. Even though a number of chemotactic factors have been identified, the regulation of the chemotactic response is not clearly understood. As the release of arachidonic acid has been implicated in monocyte chemotaxis, we studied the influence of LDL, which can supply this fatty acid to cells, on the chemotactic mobility of monocytes. Migration of human monocytic U937 cells was abolished by a 30-hour incubation in medium containing lipoprotein-depleted 10% fetal calf serum. Thereafter, human VLDL, LDL, acetyl LDL, methyl LDL, HDL, free cholesterol, linoleic acid, oleic acid, or arachidonic acid was added. At the end of varying incubation periods (0.5 to 8 hours), chemotaxis, viability, and cellular cholesterol content were measured. In the same experimental setting we also studied the effects of the pharmacological agents chloroquine, indomethacin, and acetylsalicylic acid on LDL-mediated chemotaxis. Chemotaxis was restored by LDL in a dose- and time-dependent manner starting at concentrations as low as 5 micrograms/mL and at incubations as brief as 30 minutes. The other lipoproteins tested (VLDL, HDL, acetyl LDL, and methyl LDL) as well as free cholesterol had no comparable effect on chemotaxis. Viability and total cholesterol content did not differ among the groups. Simultaneous incubation of cells with chloroquine, indomethacin, and acetylsalicylic acid reduced restitution of chemotaxis by LDL by 71%, 82%, and 68%, respectively. In contrast, the agents had only slight inhibitory effects on the chemotactic mobility of serum-fed control cells. Incubation with linoleic acid showed a 60% restoration of chemotaxis, whereas arachidonic acid stimulated chemotaxis by 140% compared with the positive control. Preincubation of LDL with the monoclonal antibody MB47 directed against LDL resulted in a significantly reduced migratory response. The data suggest a novel cyclooxygenase-dependent regulatory mechanism of chemotaxis by LDL.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8977452     DOI: 10.1161/01.atv.16.12.1481

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  6 in total

1.  New model for studying the migration of immune cells into intestinal epithelial cell monolayers.

Authors:  Akira Mori; Hideo Satsu; Makoto Shimizu
Journal:  Cytotechnology       Date:  2003-11       Impact factor: 2.058

2.  Host derived inflammatory phospholipids regulate rahU (PA0122) gene, protein, and biofilm formation in Pseudomonas aeruginosa.

Authors:  Jayasimha Rao; Antonio DiGiandomenico; Mykhaylo Artamonov; Norbert Leitinger; Ashok R Amin; Joanna B Goldberg
Journal:  Cell Immunol       Date:  2011-05-05       Impact factor: 4.868

Review 3.  Cyclooxygenase-2 inhibition: vascular inflammation and cardiovascular risk.

Authors:  Francesco Cipollone; Maria Luigia Fazia
Journal:  Curr Atheroscler Rep       Date:  2006-05       Impact factor: 5.113

4.  Modulation of cell-substrate adhesion by arachidonic acid: lipoxygenase regulates cell spreading and ERK1/2-inducible cyclooxygenase regulates cell migration in NIH-3T3 fibroblasts.

Authors:  R A Stockton; B S Jacobson
Journal:  Mol Biol Cell       Date:  2001-07       Impact factor: 4.138

5.  Inhibitory effects of human serum on human fetal skin fibroblast migration: migration-inhibitory activity and substances in serum, and its age-related changes.

Authors:  H Kondo; Y Yonezawa; H Ito
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000-04       Impact factor: 2.416

6.  Terminalia chebula Fructus Inhibits Migration and Proliferation of Vascular Smooth Muscle Cells and Production of Inflammatory Mediators in RAW 264.7.

Authors:  Hyun-Ho Lee; Keshav Raj Paudel; Dong-Wook Kim
Journal:  Evid Based Complement Alternat Med       Date:  2015-02-16       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.